霍奇金淋巴瘤序贯化疗临床研究

Clinical research on Hodgkin's lymphoma with sequential chemotherapy

目的探讨初治的霍奇金淋巴瘤(HL)更为安全有效的化疗方案。方法对36例～期HL患者,用3周期COP方案(环磷酰胺+长春新碱+强的松),后用3周期ABVD方案(盐酸吡柔比星+博来霉素+长春新碱+氮烯米胺),完成6周期化疗后根据具体情况给予放疗。结果完成化疗后,完全缓解(CR)29例(80.6%),部份缓解(PR)4例(11.1%),稳定(SD)2例5.4%,进展(PD)1例(2.6%),1年总生存率91.7%,2年总生存率88.9%。结论HL采用COP方案3周期、ABVD方案3周期序贯化疗效果好,心肌损害、肝损害轻,肺纤维化发生风险小,价格低。

Objective To explore safe and effective chemotherapy on Hodgykin＇s lymphomas （HL）. Methods 36 patients with HL were treated with COP （CPA ＋ vincristine ＋ prednisone） and ABVD （THP ＋ Bleomytin ＋ vincristine ＋ Dacarbazine） for 3 course, respectively. Radiotherapy was used according the condition of the patients. Result The rate of completely remission ）, partial remission, non-change and progression were 81% （29/36）, 11% （4/ 36）, 5.4% （2/36） and 2.6%（1/36）, respectively. The survival rate 1 and 2 is 92% （33/36） and 88.9% （32/36）, respectively. Conclusion It is effective, safe and cheap to treat HL with COP and ABVD for 3 course.